Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
10743808 | Maturitas | 2005 | 9 Pages |
Abstract
Especially for high-risk women, all the aforementioned measures may be not enough, and chemo-prevention should be considered. The use of selective oestrogen receptor modulators (SERMs) to reduce breast cancer risk is still being evaluated. Tamoxifen was the first SERM approved for the reduction of breast cancer incidence in women at high risk. However its use has limitations, due to significant side effects. Raloxifene has been approved for the prevention and treatment of post-menopausal osteoporosis and has provided excellent indications of breast cancer risk reduction, with a more favourable profile than tamoxifen.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Ageing
Authors
Fernanda Águas, Amália Martins, Tereza P. Gomes, Mário de Sousa, Daniel P. Silva, For the Portuguese Menopause Society and Portuguese Gynaecology Society For the Portuguese Menopause Society and Portuguese Gynaecology Society,